Sponsor:
Massachusetts General Hospital
Code:
NCT04842266
Conditions
Cancer Metastatic
Trauma
Pathologic Fracture
Eligibility Criteria
Sex: All
Age: 21+
Healthy Volunteers: Not accepted
Interventions
IlluminOss pelvic implant for oncologic indication
IlluminOss pelvic implant for geriatric trauma indication
Brief summary:
Conditions
Cancer Metastatic
Trauma
Pathologic Fracture
Study ID
NCT04842266
Start date
Nov 18, 2021
Status verified date
Jan, 2026
Completion date
Dec, 2027
Anticipated
Primary completion date
Nov, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 21+
Healthy Volunteers: Not accepted
Enrollment
100 participants
Anticipated
Arms
Impending or actual non-displaced or minimally displaced pathologic fractures of the pelvis
Pelvic fragility fracture in a geriatric patients (age 65 or older)
Interventions
IlluminOss pelvic implant for oncologic indication
IlluminOss pelvic implant for geriatric trauma indication
Primary outcome measure
Central contacts
Locations
Massachusetts General Hospital
Recruiting
Boston, Massachusetts, United States, 02114
Contacts
Principal Investigator:
Kevin A Raskin, MD
Sponsor
Massachusetts General Hospital
Last update posted
Jan 16, 2026
Last verified
Jan, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Massachusetts General Hospital on 2026-01-16.